N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians

[1]  A. Hoeflich,et al.  Partial phenotype conversion and differential trait response to conditions of husbandry in mice , 2017, Journal of Comparative Physiology B.

[2]  B. Ali,et al.  Studies on N‐Acetyltransferase (NAT2) Genotype Relationships in Emiratis: Confirmation of the Existence of Phenotype Variation among Slow Acetylators , 2017, Annals of human genetics.

[3]  M. Lhermitte,et al.  Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients , 2016, Toxicology reports.

[4]  M. Lee,et al.  Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity , 2016, BMC Genomics.

[5]  W. Amogne,et al.  SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine. , 2016, Omics : a journal of integrative biology.

[6]  P. Anzenbacher,et al.  Human gut microbiota plays a role in the metabolism of drugs. , 2016, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[7]  A. Sanchez‐Mazas,et al.  Variation in NAT2 acetylation phenotypes is associated with differences in food-producing subsistence modes and ecoregions in Africa , 2015, BMC Evolutionary Biology.

[8]  Jing Shi,et al.  Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis. , 2015, Pharmacogenomics.

[9]  M. Bortolini,et al.  NAT2 gene diversity and its evolutionary trajectory in the Americas , 2015, The Pharmacogenomics Journal.

[10]  C. Capelli,et al.  Exploring the relationship between lifestyles, diets and genetic adaptations in humans , 2015, BMC Genetics.

[11]  R. Altman,et al.  PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. , 2014, Pharmacogenetics and genomics.

[12]  M. Ingelman-Sundberg,et al.  High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. , 2014, Omics : a journal of integrative biology.

[13]  E. Sim,et al.  Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery , 2014, British journal of pharmacology.

[14]  Lawrence A. David,et al.  Diet rapidly and reproducibly alters the human gut microbiome , 2013, Nature.

[15]  H. McIlleron,et al.  Serum drug concentrations predictive of pulmonary tuberculosis outcomes. , 2013, The Journal of infectious diseases.

[16]  I. Kawase,et al.  NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy , 2012, European Journal of Clinical Pharmacology.

[17]  L. Bertilsson,et al.  Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients , 2012, The Pharmacogenomics Journal.

[18]  Shakir Ali,et al.  Prevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory , 2012, SpringerPlus.

[19]  L. Bertilsson,et al.  Comparison of N‐Acetyltransferase‐2 Enzyme Genotype‐Phenotype and Xanthine Oxidase Enzyme Activity Between Swedes and Koreans , 2012, Journal of clinical pharmacology.

[20]  M. Hutz,et al.  Accuracy of NAT2 SNP genotyping panels to infer acetylator phenotypes in African, Asian, Amerindian and admixed populations. , 2012, Pharmacogenomics.

[21]  S. Xie,et al.  NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis [Review article]. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[22]  L. Lindquist,et al.  Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients , 2011, PloS one.

[23]  S. Janković,et al.  N‐acetyltransferase‐2 (NAT2) Gene Polymorphisms and Enzyme Activity in Serbs: Unprecedented High Prevalence of Rapid Acetylators in a White Population , 2011, Journal of clinical pharmacology.

[24]  A. Sabbagh,et al.  Arylamine N-Acetyltransferase 2 (NAT2) Genetic Diversity and Traditional Subsistence: A Worldwide Population Survey , 2011, PloS one.

[25]  U. Diczfalusy,et al.  Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians , 2011, The Pharmacogenomics Journal.

[26]  G. Perry,et al.  Evolutionary adaptations to dietary changes. , 2010, Annual review of nutrition.

[27]  J. Muscat,et al.  Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers. , 2008, Biochemical Pharmacology.

[28]  A. Novelletto,et al.  Multiple Advantageous Amino Acid Variants in the NAT2 Gene in Human Populations , 2008, PloS one.

[29]  E. García-Martín.  Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. , 2008, Current drug metabolism.

[30]  H. Halkin,et al.  VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. , 2008, Blood.

[31]  A. Aseffa,et al.  Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients , 2008, PloS one.

[32]  A. Langaney,et al.  Worldwide distribution of NAT2 diversity: Implications for NAT2 evolutionary history , 2008, BMC Genetics.

[33]  E. Heyer,et al.  Population genetic diversity of the NAT2 gene supports a role of acetylation in human adaptation to farming in Central Asia , 2008, European Journal of Human Genetics.

[34]  P. V. Helden,et al.  The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid , 2007, European Journal of Clinical Pharmacology.

[35]  T. Brüning,et al.  Concordance between the deduced acetylation status generated by high-speed: real-time PCR based NAT2 genotyping of seven single nucleotide polymorphisms and human NAT2 phenotypes determined by a caffeine assay. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[36]  R. Straka,et al.  Discordance Between N‐acetyltransferase 2 Phenotype and Genotype in a Population of Hmong Subjects , 2006, Journal of clinical pharmacology.

[37]  U. Fuhr,et al.  Should We Use N-Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses? , 2005, Antimicrobial Agents and Chemotherapy.

[38]  S. Selinski,et al.  Re-investigation of the concordance of human NAT2 phenotypes and genotypes , 2005, Archives of Toxicology.

[39]  M. Ingelman-Sundberg,et al.  Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. , 2003, Molecular pharmacology.

[40]  M. Ingelman-Sundberg,et al.  Xanthine oxidase activity is influenced by environmental factors in Ethiopians , 2003, European Journal of Clinical Pharmacology.

[41]  M. Ingelman-Sundberg,et al.  Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. , 2002, Pharmacogenetics.

[42]  R. MacArthur,et al.  Acetylator Phenotype and Genotype in HIV‐Infected Patients with and without Sulfonamide Hypersensitivity , 2002, Journal of clinical pharmacology.

[43]  B. Leyland-Jones,et al.  Stability of 5-acetamido-6-formylamino-3-methyluracil in buffers and urine. , 2002, Journal of pharmaceutical and biomedical analysis.

[44]  A. Seow,et al.  Correlation between acetylation phenotype and genotype in Chinese women , 2000, European Journal of Clinical Pharmacology.

[45]  C. Alm,et al.  Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. , 2000, Therapeutic drug monitoring.

[46]  P. Beaune,et al.  Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. , 1996, Pharmacogenetics (London).

[47]  G. Tucker,et al.  Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--hypothesis testing. , 1989, British journal of clinical pharmacology.

[48]  Jeremy K Nicholson,et al.  Gut microbiome interactions with drug metabolism, efficacy, and toxicity. , 2017, Translational research : the journal of laboratory and clinical medicine.

[49]  M. Doll,et al.  Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. , 2012, Pharmacogenomics.

[50]  M. Banerjee,et al.  Arylamine N-acetyltransferase 2 polymorphism in the ethnic populations of South India. , 2003, International journal of molecular medicine.

[51]  T. Buclin,et al.  NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios. , 2003, British journal of clinical pharmacology.